Delving into the Latest Updates on LCRF-0004 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

RTKs

Action

inhibitors

Mechanism

RTK inhibitors(Receptor protein-tyrosine kinase inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Chem Systems, Inc.

Active Organization

Chem Systems, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

New fused bicyclic lactam head groups as rigidified analogs of thieno[3,2-b]pyridine-based kinase inhibitor LCRF-0004 were designed and synthesized. Depending on the functionalities and the size of these bicyclic head groups, potent inhibitors of RON tyrosine kinase with various level of selectivity against c-Met tyrosine kinase were obtained.

01 Jun 2015·Bioorganic & medicinal chemistry lettersQ4 · MEDICINE

Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor

Q4 · MEDICINE

Article

Author: Raeppel, Stéphane L ; Therrien, Eric ; Raeppel, Franck

New carboxamide head group analogs of thieno[3,2-b]pyridine-based kinase inhibitor LCRF-0004 were designed and synthesized. Potent and selective inhibitors of RON enzyme versus c-Met RTK were obtained.

100 Deals associated with LCRF-0004

Login to view more data